CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • TVTX Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Travere Therapeutics (TVTX)

Company Profile
Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.
Travere Therapeutics logo

Company profile

Ticker
TVTX
Exchange
NASDAQ
Website
www..travere.com
CEO
Eric Dube
Employees
Incorporated
California
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
Former names
Desert Gateway, Inc., Retrophin, Inc.
SEC CIK
0001438533
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
Travere Therapeutics Pharmaceutical, Inc. • Travere Therapeutics Ireland Limited • Travere Therapeutics Switzerland GmbH • Travere Therapeutics Research Ltd • Travere Therapeutics US Holdings, LLC • Kyalin Biosciences, Inc. • Manchester Pharmaceuticals LLC ...
IRS number
262383102

TVTX stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$30.67
Low target
$22.00
High target
$42.00
Piper Sandler
Maintains
Overweight
$42.00
11 Jan 23
Stifel
Initiated
Hold
$22.00
14 Dec 22
Wells Fargo
Initiated
Overweight
$28.00
5 Dec 22
Latest filings (excl ownership)
View all
8-K
Travere Therapeutics Provides Corporate Update and 2023 Outlook
9 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Travere Therapeutics Reports Third Quarter 2022 Financial Results
27 Oct 22
8-K
Other Events
13 Oct 22
8-K
Other Events
22 Aug 22
S-8
Registration of securities for employees
18 Aug 22
8-K/A
Departure of Directors or Certain Officers
17 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Travere Therapeutics Reports Second Quarter 2022 Financial Results
4 Aug 22
8-K
Other Events
16 May 22
Transcripts
View all
TVTX
Earnings call transcript
2022 Q3
28 Oct 22
TVTX
Earnings call transcript
2022 Q2
7 Aug 22
TVTX
Earnings call transcript
2022 Q1
8 May 22
TVTX
Earnings call transcript
2021 Q4
25 Feb 22
TVTX
Earnings call transcript
2021 Q3
29 Oct 21
TVTX
Earnings call transcript
2021 Q2
31 Jul 21
TVTX
Earnings call transcript
2021 Q1
9 May 21
TVTX
Earnings call transcript
2020 Q4
2 Mar 21
TVTX
Earnings call transcript
2020 Q3
8 Nov 20
TVTX
Earnings call transcript
2020 Q2
2 Aug 20
Latest ownership filings
View all
4
Sandra Calvin
26 Jan 23
4
WILLIAM E. ROTE
26 Jan 23
4
ELIZABETH E REED
26 Jan 23
4
Eric M Dube
26 Jan 23
4
Christopher R. Cline
26 Jan 23
4
Peter Heerma
26 Jan 23
4
Eric M Dube
6 Jan 23
4
Jula Inrig
6 Jan 23
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
28 Oct 22
4
Peter Heerma
6 Oct 22

Financial summary

Financial statements Chart TVTX financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 151.34 mm 151.34 mm 151.34 mm 151.34 mm 151.34 mm 151.34 mm
Cash burn (monthly) 9.47 mm (no burn) 23.17 mm 22.00 mm 13.18 mm 13.21 mm
Cash used (since last report) 36.95 mm n/a 90.38 mm 85.81 mm 51.39 mm 51.53 mm
Cash remaining 114.38 mm n/a 60.96 mm 65.53 mm 99.95 mm 99.81 mm
Runway (months of cash) 12.1 n/a 2.6 3.0 7.6 7.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

TVTX institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 171 171 –
Opened positions 24 21 +14.3%
Closed positions 24 24 –
Increased positions 62 55 +12.7%
Reduced positions 54 67 -19.4%
13F shares Current Prev Q Change
Total value 1.71 bn 2.14 bn -20.2%
Total shares 68.97 mm 72.26 mm -4.5%
Total puts 99.10 k 78.20 k +26.7%
Total calls 338.20 k 107.60 k +214.3%
Total put/call ratio 0.3 0.7 -59.7%
Largest owners Shares Value Change
Armistice Capital 5.84 mm $143.80 mm +9.7%
Ra Capital Management 4.92 mm $121.30 mm 0.0%
BLK Blackrock 4.56 mm $112.48 mm +1.4%
Deep Track Capital 4.00 mm $98.56 mm +11.7%
JHG Janus Henderson 3.91 mm $96.40 mm -3.1%
Vanguard 3.38 mm $83.32 mm +1.5%
MCQEF Macquarie 3.31 mm $81.59 mm -9.8%
Baker Bros. Advisors 3.30 mm $81.31 mm 0.0%
GS Goldman Sachs 2.55 mm $62.93 mm -2.2%
Adage Capital Partners GP, L.L.C. 2.35 mm $57.90 mm +20.5%
Largest transactions Shares Bought/sold Change
STT State Street 0.00 -3.61 mm EXIT
VR Adviser 0.00 -1.71 mm EXIT
Kynam Capital Management 416.73 k -818.42 k -66.3%
Armistice Capital 5.84 mm +516.00 k +9.7%
Orbimed Advisors 1.25 mm +480.93 k +62.3%
Perceptive Advisors 90.75 k -479.34 k -84.1%
Healthcare Of Ontario Pension Plan Trust Fund 756.00 k +445.50 k +143.5%
Finepoint Capital 1.03 mm +444.58 k +76.1%
Deep Track Capital 4.00 mm +419.30 k +11.7%
Millennium Management 599.00 k +406.18 k +210.7%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

TVTX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
25 Jan 23 Sandra Calvin Common Stock Sell Dispose S No Yes 21.63 192 4.15 k 34,836
24 Jan 23 Rote William E. Common Stock Sell Dispose S No Yes 21.5 2,062 44.33 k 42,376
24 Jan 23 Reed Elizabeth E Common Stock Sell Dispose S No Yes 21.5 2,062 44.33 k 39,776
24 Jan 23 Eric M Dube Common Stock Sell Dispose S No Yes 21.5 6,442 138.50 k 147,846
24 Jan 23 Christopher R. Cline Common Stock Sell Dispose S No No 21.9044 852 18.66 k 32,871
24 Jan 23 Sandra Calvin Common Stock Sell Dispose S No No 21.9044 905 19.82 k 35,028
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $42
11 Jan 23
Piper Sandler analyst Do Kim maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $38 to $42.
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
14 Dec 22
Stifel Initiates Coverage On Travere Therapeutics with Hold Rating, Announces Price Target of $22
14 Dec 22
Stifel analyst Alex Thompson initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Hold rating and announces Price Target of $22.
Stocks That Hit 52-Week Lows On Monday
12 Dec 22
4 Analysts Have This to Say About Travere Therapeutics
5 Dec 22

Press releases

From Benzinga Pro
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jan 23
SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on January 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Dec 22
SAN DIEGO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on December 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Nov 22
Travere Therapeutics to Present at Upcoming Investor Conferences
9 Nov 22
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn